5 February 2019 - - US-based biotechnology company Cedilla Therapeutics has appointed a veteran biopharma executive, Andrew Dawson, as chief human resources officer, the company said.

Dawson brings a wealth of experience in company growth and culture development, as well as talent acquisition and coaching.

Dawson brings more than 20 years of global experience in human resources across the biotech and pharmaceutical industries.

He joins Cedilla after having served in senior roles of increasing scope and responsibility at Shire, Roche, Novartis, Eli Lilly and TripAdvisor.

Most recently, he was a senior vice president and head of human resources at Enzyvant, leading the worldwide human resources function and serving as a member of the executive leadership team.

Dawson received his M.Sc. in human resources management and development from the University of Salford in Manchester, England.

Cedilla Therapeutics is discovering and exploiting unique insights into protein stability. Cedilla's integrated, multi-faceted approach has the potential to broaden the reach of small molecules by generating therapeutics that degrade protein targets as their primary mechanism of action.

The approach harnesses intrinsic degradation pathways that are upstream of ubiquitination. Cedilla is focused on destabilizing oncoprotein targets using a product engine that is also applicable to targets outside of oncology.

Cedilla was launched in 2018 by Third Rock Ventures and is based in Cambridge, Mass.